pcsk9

PCSK9

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor LDL-R by binding LDL-R, reducing low-density lipoprotein cholesterol (LDL-C) clearance. In addition to regulating LDL-R, PCSK9 inhibitors can also bind Toll-like receptors (TLRs), SCARB1 scavenger receptor B (SR-B/CD36), low-density lipoprotein receptor-related protein 1 (LRP1), apolipoprotein E receptor-2 (ApoER2) and very-low-density lipoprotein receptor (VLDL-R) reducing the lipoprotein concentration and slowing thrombosis. In addition to cardiovascular diseases, PCSK9 is also used in pancreatic cancer, sepsis, and Parkinson's disease. Currently marketed PCSK9 inhibitors include alirocumab, evolocumab, and inclisiran, as well as small molecules, nucleic acid drugs, and vaccines under development 1).

Conventional lipid-lowering agents, including statins, ezetimibe, fibrates, bile acid sequestrants, nicotinic acid, bempedoic acid and Omega-3 fatty acid, are essential to the management of dyslipidemia. However, these agents have been shown to increase the level of plasma proprotein convertase subtilisin/kexin 9 (PCSK9), a serine protease associated with increased - cardiovascular risk.

A review of Luo et al. aimed to investigate the impact of commonly available conventional lipid-lowering agents on circulating PCSK9 levels and lipid profiles.

This protocol was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. A systematic literature search will be conducted in the following databases: MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, Web of Science, SCOPUS and ScienceDirect. Additional information will be retrieved from clinical trial registries or from reference list searches. Published and peer-reviewed randomised controlled trials with adults receiving statin, ezetimibe, fibrate, bile acid sequestrant, nicotinic acid, bempedoic acid or Omega-3 monotherapy or in combination for at least 2 weeks, with availability of plasma PCSK9 at the beginning and end of treatment or the net changes in values, will be included. Study selection, data extraction and assessment of the risk of bias will be independently conducted by two investigators. Continuous data will be presented as a standardised mean difference with 95% confidence interval (CI) and dichotomous data as risk ratios with 95% CI. Subgroup analysis and sensitivity analysis will be performed when sufficient studies are included. Publication bias will be assessed with a funnel plot and Egger's test. 2). 3)


4: Ghaleb Y, Elbitar S, Philippi A, El Khoury P, Azar Y, Andrianirina M, Loste A, Abou-Khalil Y, Nicolas G, Le Borgne M, Moulin P, Di-Filippo M, Charrière S, Farnier M, Yelnick C, Carreau V, Ferrières J, Lecerf JM, Derksen A, Bernard G, Gauthier MS, Coulombe B, Lütjohann D, Fin B, Boland A, Olaso R, Deleuze JF, Rabès JP, Boileau C, Abifadel M, Varret M. Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia. Metabolites. 2022 Mar 18;12(3):262. doi: 10.3390/metabo12030262. PMID: 35323704; PMCID: PMC8955453.

5: Ji J, Feng M, Niu X, Zhang X, Wang Y. Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR). Bioengineered. 2021 Dec;12(1):8057-8066. doi: 10.1080/21655979.2021.1982304. PMID: 34666623; PMCID: PMC8806487.

6: Liu X, Guo JW, Lin XC, Tuo YH, Peng WL, He SY, Li ZQ, Ye YC, Yu J, Zhang FR, Ma MM, Shang JY, Lv XF, Zhou AD, Ouyang Y, Wang C, Pang RP, Sun JX, Ou JS, Zhou JG, Liang SJ. Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms. Eur Heart J. 2021 Dec 14;42(47):4847-4861. doi: 10.1093/eurheartj/ehab660. PMID: 34570211.

7: Hirsh Raccah B, Yanovsky A, Treves N, Rotshild V, Renoux C, Danenberg H, Eliaz R, Matok I. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression. Int J Cardiol. 2021 Jul 15;335:7-14. doi: 10.1016/j.ijcard.2021.04.025. Epub 2021 Apr 20. PMID: 33892045.

8: Schlunk F, Fischer P, Princen HMG, Rex A, Prinz V, Foddis M, Lütjohann D, Laufs U, Endres M. Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice. Stroke. 2020 Nov;51(11):e297-e298. doi: 10.1161/STROKEAHA.120.030087. Epub 2020 Oct 19. PMID: 33070710.

9: Schlunk F, Fischer P, Princen HMG, Rex A, Prinz V, Foddis M, Lütjohann D, Laufs U, Endres M. No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice. Behav Brain Res. 2021 Jan 1;396:112875. doi: 10.1016/j.bbr.2020.112875. Epub 2020 Aug 25. PMID: 32858115.

10: Schmidt AF, Holmes MV, Preiss D, Swerdlow DI, Denaxas S, Fatemifar G, Faraway R, Finan C, Valentine D, Fairhurst-Hunter Z, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh K, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Lill CM, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben- Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques- Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott RA, Luan J, Bobak M, Malyutina S, Pająk A, Kubinova R, Tamosiunas A, Pikhart H, Grarup N, Pedersen O, Hansen T, Linneberg A, Jess T, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Lester KH, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, Scott R, Schofield P, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H; Lifelines Cohort authors; Christen T, Mook-Kanamori DO; ICBP Consortium; Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dörr M, Lerch MM, Völker U, Völzke H, Ward J, Pell JP, Meade T, Christophersen IE, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Roussel R, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Hopewell JC, Seshadri S; METASTROKE Consortium of the ISGC; Dale C, Costa RPE, Ridker PM, Chasman DI, Reiner AP, Ritchie MD, Lange LA, Cornish AJ, Dobbins SE, Hemminki K, Kinnersley B, Sanson M, Labreche K, Simon M, Bondy M, Law P, Speedy H, Allan J, Li N, Went M, Weinhold N, Morgan G, Sonneveld P, Nilsson B, Goldschmidt H, Sud A, Engert A, Hansson M, Hemingway H, Asselbergs FW, Patel RS, Keating BJ, Sattar N, Houlston R, Casas JP, Hingorani AD. Phenome-wide association analysis of LDL- cholesterol lowering genetic variants in PCSK9. BMC Cardiovasc Disord. 2019 Oct 29;19(1):240. doi: 10.1186/s12872-019-1187-z. PMID: 31664920; PMCID: PMC6820948.

11: Shingai Y, Kimura N, Doijiri R, Takahashi K, Yokosawa M, Kanoke A, Kikuchi T, Sugawara T, Tominaga T. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting. World Neurosurg. 2020 Mar;135:e36-e42. doi: 10.1016/j.wneu.2019.10.095. Epub 2019 Oct 23. PMID: 31655235.

12: Blaeschke F, Paul MC, Schuhmann MU, Rabsteyn A, Schroeder C, Casadei N, Matthes J, Mohr C, Lotfi R, Wagner B, Kaeuferle T, Feucht J, Willier S, Handgretinger R, StevanoviĆ S, Lang P, Feuchtinger T. Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. Cytotherapy. 2019 Sep;21(9):973-986. doi: 10.1016/j.jcyt.2019.06.009. Epub 2019 Jul 25. PMID: 31351799.

13: Ogata A, Oho K, Matsumoto N, Masuoka J, Inoue K, Koguchi M, Yoshioka F, Abe T. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. Acta Neurochir (Wien). 2019 Mar;161(3):597-600. doi: 10.1007/s00701-019-03825-4. Epub 2019 Feb 7. PMID: 30729307.

14: Can A, Castro VM, Dligach D, Finan S, Yu S, Gainer V, Shadick NA, Savova G, Murphy S, Cai T, Weiss ST, Du R. Lipid-Lowering Agents and High HDL (High- Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture. Stroke. 2018 May;49(5):1148-1154. doi: 10.1161/STROKEAHA.117.019972. Epub 2018 Apr 5. PMID: 29622625; PMCID: PMC5915939.

15: Harrison SC, Holmes MV, Burgess S, Asselbergs FW, Jones GT, Baas AF, van 't Hof FN, de Bakker PIW, Blankensteijn JD, Powell JT, Saratzis A, de Borst GJ, Swerdlow DI, van der Graaf Y, van Rij AM, Carey DJ, Elmore JR, Tromp G, Kuivaniemi H, Sayers RD, Samani NJ, Bown MJ, Humphries SE. Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta- analysis. JAMA Cardiol. 2018 Jan 1;3(1):26-33. doi: 10.1001/jamacardio.2017.4293. Erratum in: JAMA Cardiol. 2018 Jan 1;3(1):90. PMID: 29188294; PMCID: PMC5833524.

16: Piao MX, Bai JW, Zhang PF, Zhang YZ. PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways. Int J Clin Exp Pathol. 2015 Mar 1;8(3):2787-94. PMID: 26045785; PMCID: PMC4440094.


1)
Liu C, Chen J, Chen H, Zhang T, He D, Luo Q, Chi J, Hong Z, Liao Y, Zhang S, Wu Q, Cen H, Chen G, Li J, Wang L. PCSK9 Inhibition: From Current Advances to Evolving Future. Cells. 2022 Sep 23;11(19):2972. doi: 10.3390/cells11192972. PMID: 36230934; PMCID: PMC9562883.
2)
Luo J, Huang T, Xu R, Wang X, Yang Y, Li L, Zhang X, Zhang Y, Yang R, Wang J, Yang H, Ma Y, Yang B, Wang T, Jiao L. Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022 Sep 8;12(9):e061884. doi: 10.1136/bmjopen-2022-061884. PMID: 36691198.
3)
Luo J, Liao W, Wang X, Xu R, Li W, Li W, Liu K, Huang K, Ma Y, Wang T, Yang B, Jiao L. PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022 Nov 24;12(11):e062046. doi: 10.1136/bmjopen-2022-062046. PMID: 36424111; PMCID: PMC9693878.
  • pcsk9.txt
  • Last modified: 2023/01/24 09:22
  • by administrador